市場調查報告書

全身型重症肌無力(gMG):市場洞察,流行病學,到2028年前的市場預測

Generalized Myasthenia Gravis (gMG) - Market Insights, Epidemiology, and Market Forecast-2028

出版商 DelveInsight Business Research LLP 商品編碼 905938
出版日期 內容資訊 英文 215 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全身型重症肌無力(gMG):市場洞察,流行病學,到2028年前的市場預測 Generalized Myasthenia Gravis (gMG) - Market Insights, Epidemiology, and Market Forecast-2028
出版日期: 2019年08月01日內容資訊: 英文 215 Pages
簡介

本報告提供全球全身型重症肌無力(gMG)市場的相關調查,提供疾病概要,現在上市的主要藥物,新開發的主要藥物,美國·德國·法國·義大利·西班牙·英國·日本等主要7個國家的市場分析等資訊。

目錄

第1章 重要的洞察

第2章 全身型重症肌無力市場概要

  • 2017年:市場佔有率(%)分佈
  • 2028年:市場佔有率(%)分佈

第3章 疾病概要:全身型重症肌無力

  • 簡介
  • 重症肌無力的種類
    • 眼部重症肌無力
    • 全身型重症肌無力
  • 重症肌無力的MGFA分類
  • 病因
  • 危險因素
  • 徵兆及症狀
  • 重症肌無力的合併症
  • 遺傳的根據
  • 病理生理學
    • 自身抗體
    • 補數連鎖
  • 生物標記
  • 診斷
    • 鑑別診斷
    • 日本的診斷標準

第4章 流行病學及患者人口

  • 主要調查結果
  • 人口及預測參數
  • 主要7個國家的整體患者數
  • 各國流行病學
  • 美國
    • 假設和根據
    • 美國整體診斷案例
    • 自我抗體-美國的病例
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第5章 目前治療方法

  • 重症肌無力的管理相關國際共識指導
  • 重症肌無力的診斷和治療相關義大利的建議
  • 重症肌無力的德國神經學會指南
  • 重症肌無力的日本臨床指南

第6章 潛在的需求

第7章 所販售藥物

  • 主要企業的藥物
  • Soliris: Alexion Pharmaceuticals
    • 藥的說明
    • 法規的里程碑
    • 優點及缺點
    • 臨床開發
    • 安全性及有效性
    • 產品簡介
  • Mestinon: Valeant Pharmaceuticals
  • Prograf: Astellas Pharma Inc.株式會社
  • Venoglobulin IH: 田邊三菱製藥株式會社

第8章 新的治療方法

  • 主要企業的藥物
  • Firdapse: Catalyst Pharmaceuticals
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性及有效性
    • 產品簡介
  • Hizentra: CSL Behring
  • Rozanolixizumab: UCB Pharma
  • Efgartigimod : Argenx
  • Zilucoplan: Ra Pharmaceuticals
  • Ravulizumab: Alexion Pharmaceuticals
  • IMVT-1401: Immunovant
    • 其他開發活動
  • M281: Momenta Pharmaceuticals
  • CV-MG01: CuraVac
  • IGIV-C: Grifols Therapeutics
  • CFZ533: Novartis

第9章 全身型重症肌無力:7個主要的市場分析

  • 主要調查結果
  • 主要7個國家的市場規模
  • 各國市場預測
  • 美國:市場預測
    • 美國的市場規模
    • 全身型重症肌無力的整體市場規模
    • 第1選擇療法:各市場規模
    • 第2選擇療法:各市場規模
  • 歐洲5個國家:市場預測
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本:市場預測

第10章 市場成長要素

第11章 市場障礙

第12章 附錄

第13章 報告方法

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

第17章 免責聲明

目錄
Product Code: DIMI0670

DelveInsight's 'Generalized Myasthenia Gravis (gMG)-Market Insights, Epidemiology, and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of gMG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted market size of Generalized Myasthenia Gravis (gMG) from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Generalized Myasthenia Gravis (gMG) - Disease Understanding and Treatment Algorithm

The DelveInsight's Generalized Myasthenia Gravis (gMG) market report gives a thorough understanding of the Myasthenia Gravis by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Myasthenia Gravis in the US, Europe, and Japan.

Generalized Myasthenia Gravis (gMG) Epidemiology

The Generalized Myasthenia Gravis (gMG) epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Generalized Myasthenia Gravis (gMG) in the 7MM. The epidemiology is segmented by total diagnosed prevalent cases, auto-antibodies specific cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK) and Japan from 2017-2028.

According to DelveInsight, total diagnosed prevalent population of Generalized Myasthenia Gravis (gMG) in seven major markets was found to be 58,828 in 2017. The estimates suggest a higher diagnosed prevalence of gMG in the United States with 32,188 cases in 2017. Among EU5, Spain had the highest diagnosed prevalent population of Gmg, whereas France had the lowest cases.

Generalized Myasthenia Gravis (gMG) Drug Chapters

This segment of the Generalized Myasthenia Gravis (gMG) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market size of Generalized Myasthenia Gravis (gMG) is mainly accounted by symptomatic treatments comprising acetylcholinesterase Inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid-acting short-term immunomodulators (intravenous immunoglobulin, plasma exchange), and procedures (thymectomy).

Recently, Soliris (Eculizumab) (Alexion Pharmaceuticals) got approval for MG treatment in 2017. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies, it has significantly impacted the market size of Myasthenia Gravis after its launch.

Generalized Myasthenia Gravis (gMG) Market Outlook

The Generalized Myasthenia Gravis (gMG) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Generalized Myasthenia Gravis in 7MM was found to be USD 2,602 million in 2017. The United States accounts for the largest market size of Generalized Myasthenia Gravis, in comparison to EU5 (Germany, France, Italy, Spain, and the UK), and Japan.

This market is further expected to grow during the forecasted period of 2019-2028 owing to the launch of upcoming therapies. Detailed chapter for upcoming therapies, like Rozanolixizumab (UCB Pharma); CFZ533 (Novartis); Efgartigimod (Argenx); Zilucoplan (Ra Pharmaceuticals); Firdapse (Catalyst Pharmaceuticals); Hizentra (CSL Behring); Ravulizumab (Alexion Pharmaceuticals); IMVT-1401 (Immunovant); M281 (Momenta Pharmaceuticals); CV-MGO1(CuraVac), and others have also been covered in the report, are expected to enter the MG market by 2028. The market is further divided based on the available and upcoming drugs in to first and second-line of therapies.

Generalized Myasthenia Gravis (gMG) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Generalized Myasthenia Gravis (gMG) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Generalized Myasthenia Gravis (gMG) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Generalized Myasthenia Gravis (gMG) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Myasthenia Gravis market.
  • Organize sales and marketing efforts by identifying the best opportunities for Generalized Myasthenia Gravis (gMG) market.
  • To understand the future market competition in the Generalized Myasthenia Gravis (gMG) market.

Table of Contents

1. Key Insights

2. Generalized Myasthenia Gravis Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of gMG in 2017
  • 2.2. Market Share (%) Distribution of gMG in 2028

3. Disease Overview: Generalized Myasthenia Gravis

  • 3.1. Introduction
  • 3.2. Types of Myasthenia Gravis
    • 3.2.1. Ocular Myasthenia Gravis
    • 3.2.2. Generalized Myasthenia Gravis
  • 3.3. MGFA Classification of Myasthenia Gravis
  • 3.4. Etiology
  • 3.5. Risk Factors
  • 3.6. Signs and Symptoms
  • 3.7. Comorbid conditions in MG
  • 3.8. Genetic Basis of Generalized Myasthenia Gravis
  • 3.9. Pathophysiology of Generalized Myasthenia Gravis
    • 3.9.1. Autoantibodies
    • 3.9.2. Complement cascade
  • 3.10. Biomarkers in Generalized Myasthenia Gravis
  • 3.11. Diagnosis
    • 3.11.1. Differential Diagnosis
    • 3.11.2. Japanese diagnostic criteria for Myasthenia Gravis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. 7MM Total Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis
  • 4.4. Country Wise-Epidemiology of Myasthenia Gravis
  • 4.5. United States
    • 4.5.1. Assumptions and Rationale
    • 4.5.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the US
    • 4.5.3. Autoantibodies- Specific Cases of Generalized Myasthenia Gravis in the US
  • 4.6. Germany
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Germany
    • 4.6.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Germany
  • 4.7. France
    • 4.7.1. Assumptions and Rationale
    • 4.7.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in France
    • 4.7.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in France
  • 4.8. Italy
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Italy
    • 4.8.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Italy
  • 4.9. Spain
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Spain
    • 4.9.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Spain
  • 4.10. United Kingdom
    • 4.10.1. Assumptions and Rationale
    • 4.10.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in the United Kingdom
    • 4.10.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan
    • 4.11.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis in Japan

5. Current Treatment Practices

  • 5.1. International Consensus Guidance for Management of Myasthenia Gravis
  • 5.2. Italian recommendations for the diagnosis and treatment of myasthenia gravis
  • 5.3. German Neurological Society Guidelines for myasthenia gravis
  • 5.4. Japanese Clinical Guidelines for Myasthenia Gravis

6. Unmet Needs

7. Marketed drugs

  • 7.1. Key cross competition- Marketed drugs
  • 7.2. Soliris: Alexion Pharmaceuticals
    • 7.2.1. Drug Description
    • 7.2.2. Regulatory Milestones
    • 7.2.3. Advantages & Disadvantages
    • 7.2.4. Clinical Development
    • 7.2.5. Safety and Efficacy
    • 7.2.6. Product Profile
  • 7.3. Mestinon: Valeant Pharmaceuticals
    • 7.3.1. Drug Description
    • 7.3.2. Regulatory Milestones
    • 7.3.3. Advantages & Disadvantages
    • 7.3.4. Safety and Efficacy
    • 7.3.5. Product Profile
  • 7.4. Prograf: Astellas Pharma
    • 7.4.1. Drug Description
    • 7.4.2. Regulatory Milestones
    • 7.4.3. Clinical Development
    • 7.4.4. Safety and Efficacy
    • 7.4.5. Product Profile
  • 7.5. Venoglobulin IH: Mitsubishi Tanabe Pharma
    • 7.5.1. Drug Description
    • 7.5.2. Regulatory Milestones
    • 7.5.3. Advantages & Disadvantages
    • 7.5.4. Clinical Development
    • 7.5.5. Product Profile

8. Emerging Therapies

  • 8.1. Key cross competition- Emerging Therapies
  • 8.2. Firdapse: Catalyst Pharmaceuticals
    • 8.2.1. Product Description
    • 8.2.2. Other Development Activities
    • 8.2.3. Clinical Development
    • 8.2.4. Safety and Efficacy
    • 8.2.5. Product Profile
  • 8.3. Hizentra: CSL Behring
    • 8.3.1. Product Description
    • 8.3.2. Other Development Activities
    • 8.3.3. Clinical Development
    • 8.3.4. Safety and Efficacy
    • 8.3.5. Product Profile
  • 8.4. Rozanolixizumab: UCB Pharma
    • 8.4.1. Product Description
    • 8.4.2. Other Development Activities
    • 8.4.3. Clinical Development
    • 8.4.4. Safety and Efficacy
    • 8.4.5. Product Profile
  • 8.5. Efgartigimod : Argenx
    • 8.5.1. Product Description
    • 8.5.2. Other Development Activities
    • 8.5.3. Clinical Development
    • 8.5.4. Safety and Efficacy
    • 8.5.5. Product Profile
  • 8.6. Zilucoplan: Ra Pharmaceuticals
    • 8.6.1. Product Description
    • 8.6.2. Other Development Activities
    • 8.6.3. Clinical Development
    • 8.6.4. Safety and Efficacy
    • 8.6.5. Product Profile
  • 8.7. Ravulizumab: Alexion Pharmaceuticals
    • 8.7.1. Product Description
    • 8.7.2. Clinical Development
    • 8.7.3. Product Profile
  • 8.8. IMVT-1401: Immunovant
    • 8.8.1. Product Description
    • 8.8.2. Other Developmental Activities
    • 8.8.3. Clinical Development
    • 8.8.4. Safety and Efficacy
    • 8.8.5. Product Profile
  • 8.9. M281: Momenta Pharmaceuticals
    • 8.9.1. Product Description
    • 8.9.2. Clinical Development
    • 8.9.3. Safety and Efficacy
    • 8.9.4. Product Profile
  • 8.10. CV-MG01: CuraVac
    • 8.10.1. Product Description
    • 8.10.2. Other Developmental Activities
    • 8.10.3. Clinical Development
    • 8.10.4. Safety and Efficacy
    • 8.10.5. Product Profile
  • 8.11. IGIV-C: Grifols Therapeutics
    • 8.11.1. Product Description
    • 8.11.2. Other Development Activities
    • 8.11.3. Clinical Development
    • 8.11.4. Product Profile
  • 8.12. CFZ533: Novartis
    • 8.12.1. Product Description
    • 8.12.2. Clinical Development
    • 8.12.3. Product Profile

9. Generalized Myasthenia Gravis: 7 Major Market Analysis

  • 9.1. Key Findings
  • 9.2. Market Size of Generalized Myasthenia Gravis in 7MM
  • 9.3. Market Outlook by Country
  • 9.4. The United States: Market Outlook
    • 9.4.1. United States Market Size
    • 9.4.2. Total Market Size of Generalized Myasthenia Gravis
    • 9.4.3. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
    • 9.4.4. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
  • 9.5. EU-5 Countries: Market Outlook
  • 9.6. Germany
    • 9.6.1. Total Market Size of Generalized Myasthenia Gravis
    • 9.6.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
    • 9.6.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
  • 9.7. France
    • 9.7.1. Total Market Size of Generalized Myasthenia Gravis
    • 9.7.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
    • 9.7.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
  • 9.8. Italy
    • 9.8.1. Total Market Size of Generalized Myasthenia Gravis
    • 9.8.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
    • 9.8.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
  • 9.9. Spain
    • 9.9.1. Total Market Size of Generalized Myasthenia Gravis
    • 9.9.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
    • 9.9.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
  • 9.10. United Kingdom
    • 9.10.1. Total Market Size of Generalized Myasthenia Gravis
    • 9.10.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
    • 9.10.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies
  • 9.11. Japan: Market Outlook
    • 9.11.1. Total Market Size of Generalized Myasthenia Gravis
    • 9.11.2. Market Size of Generalized Myasthenia Gravis by First-Line Therapies
    • 9.11.3. Market Size of Generalized Myasthenia Gravis by Second-Line Therapies

10. Market Drivers

11. Market Barriers

12. Appendix

13. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

17. Disclaimer

List of Tables

  • Table 1: Osserman and Genkins Classification of Myasthenia Gravis, modified by the MGFA/Task Force
  • Table 2: Summary of the tests used in the diagnosis of myasthenia gravis
  • Table 3: Proposed diagnostic criteria for myasthenia gravis - Japanese Treatment guidelines
  • Table 4: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017-2028)
  • Table 5: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017-2028)
  • Table 6: Autoantibodies-specific cases of Myasthenia Gravis in the United States (2017-2028)
  • Table 7: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Table 8: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Table 9: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Table 10: Autoantibodies-specific cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Table 11: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Table 12: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Table 13: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Table 14: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Table 15: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Table 16: Autoantibodies-specific cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Table 17: Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Table 18: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Table 19: Classification of MG severity and response to therapy
  • Table 20: Japanese Clinical Guidelines for Myasthenia Gravis
  • Table 21: Japanese Treatment Strategies for Myasthenia Gravis
  • Table 22: Key cross competition- Marketed drugs
  • Table 23: Eculizumab, Clinical Trial Description, 2019
  • Table 24: Tacrolimus, Clinical Trial Description, 2018
  • Table 25: GB-0998, Clinical Trial Description, 2018
  • Table 26: Key cross competition - Emerging Therapies Phase III
  • Table 27: Key cross competition - Emerging Therapies Phase II
  • Table 28: Amifampridine Phosphate, Clinical Trial Description, 2019
  • Table 29: Hizentra, Clinical Trial Description, 2019
  • Table 30: UCB7665, Clinical Trial Description, 2019
  • Table 31: Efgartigimod, Clinical Trial Description, 2019
  • Table 32: RA101495, Clinical Trial Description, 2019
  • Table 33: RA101495, Clinical Trial Description, 2019
  • Table 34: IMVT-1401, Clinical Trial Description, 2019
  • Table 35: M281, Clinical Trial Description, 2019
  • Table 36: CV-MG01, Clinical Trial Description, 2019
  • Table 37: IGIV-C, Clinical Trial Description, 2019
  • Table 38: CFZ533, Clinical Trial Description, 2018
  • Table 39: 7 Major Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 40: United States Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 41: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Table 42: US gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Table 43: Germany Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 44: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Table 45: Germany gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Table 46: France Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 47: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Table 48: France gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Table 49: Italy, Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 50: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Table 51: Italy gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Table 52: Spain, Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 53: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Table 54: Spain gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Table 55: UK Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 56: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Table 57: UK gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Table 58: Japan, Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Table 59: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Table 60: Japan gMG Market size by Second Line Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Transmission of Nerve Impulses to Muscles
  • Figure 2: Signs and Symptoms of Generalized Myasthenia Gravis
  • Figure 3: Various Components of the Neuromuscular Junction involved in MG
  • Figure 4: Various Components of the Neuromuscular Junction involved in MG
  • Figure 5: Pathophysiology of MG at the neuromuscular junction
  • Figure 6: Complement cascade
  • Figure 7: Diagnostic testing in myasthenia gravis
  • Figure 8: Diagnosis flowchart for MG
  • Figure 9: Diagnosed Prevalent Patient Population of Generalized Myasthenia Gravis in 7MM (2017-2028)
  • Figure 10: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the United States (2017-2028)
  • Figure 11: Autoantibodies-specific cases of Myasthenia Gravis in the US (2017-2028)
  • Figure 12: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Figure 13: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Germany (2017-2028)
  • Figure 14: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Figure 15: Autoantibodies-specific cases of Generalized Myasthenia Gravis in France (2017-2028)
  • Figure 16: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Figure 17: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Italy (2017-2028)
  • Figure 18: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Figure 19: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Spain (2017-2028)
  • Figure 20: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Figure 21: Autoantibodies-specific cases of Generalized Myasthenia Gravis in the UK (2017-2028)
  • Figure 22: Total Diagnosed Prevalent cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Figure 23: Autoantibodies-specific cases of Generalized Myasthenia Gravis in Japan (2017-2028)
  • Figure 24: Treatment of Generalized Myasthenia Gravis
  • Figure 25: Treatment of Severe Myasthenia Gravis Exacerbations
  • Figure 26: Treatment flow chart: generalized myasthenia
  • Figure 27: Treatment options for MG - German Neurological Society Guidelines
  • Figure 28: Treatment strategies for MG
  • Figure 29: Treatment algorithms for chronic MG and acute MG exacerbations
  • Figure 30: Unmet Needs for Generalized Myasthenia Gravis
  • Figure 31: 7 Major Market Size of Generalized Myasthenia Gravis in USD Million (2017-2028)
  • Figure 32: Market Size of Generalized Myasthenia Gravis in the United States, USD Millions (2017-2028)
  • Figure 33: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Figure 34: US gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Figure 35: Market Size of Generalized Myasthenia Gravis in Germany, USD Millions (2017-2028)
  • Figure 36: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Figure 37: Germany gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Figure 38: Market Size of Generalized Myasthenia Gravis in France, USD Millions (2017-2028)
  • Figure 39: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Figure 40: France gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Figure 41: Market Size of Generalized Myasthenia Gravis in Italy, USD Millions (2017-2028)
  • Figure 42: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Figure 43: Italy gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Figure 44: Market Size of Generalized Myasthenia Gravis in Spain, USD Millions (2017-2028)
  • Figure 45: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Figure 46: Spain gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Figure 47: Market Size of Generalized Myasthenia Gravis in the UK, USD Millions (2017-2028)
  • Figure 48: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Figure 49: UK gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Figure 50: Market Size of Generalized Myasthenia Gravis in Japan, USD Millions (2017-2028)
  • Figure 51: Market Size of gMG by First-Line Therapies in USD Million (2017-2028)
  • Figure 52: Japan gMG Market size by Second Line Therapies in USD Million (2017-2028)
  • Figure 53: Market Drivers
  • Figure 54: Market Barriers
Back to Top